Outset Medical, Inc. (OM)
NASDAQ: OM · Real-Time Price · USD
0.790
-0.028 (-3.45%)
Jan 17, 2025, 4:00 PM EST - Market closed
Outset Medical Stock Forecast
OM's stock price has decreased by -80.92% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Outset Medical stock have an average target of 4.00, with a low estimate of 3.00 and a high estimate of 6.00. The average target predicts an increase of 406.33% from the current stock price of 0.79.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Outset Medical stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Reiterates $3 | Hold | Reiterates | $3 | +279.75% | Jan 7, 2025 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $6 → $3 | Buy → Hold | Downgrades | $6 → $3 | +279.75% | Aug 8, 2024 |
| TD Cowen | TD Cowen | Strong Buy Maintains $9 → $3 | Strong Buy | Maintains | $9 → $3 | +279.75% | Aug 8, 2024 |
| RBC Capital | RBC Capital | Hold → Buy Upgrades $5 → $6 | Hold → Buy | Upgrades | $5 → $6 | +659.49% | Jun 21, 2024 |
| BTIG | BTIG | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +659.49% | Apr 8, 2024 |
Financial Forecast
Revenue This Year
115.61M
from 130.38M
Decreased by -11.33%
Revenue Next Year
127.74M
from 115.61M
Increased by 10.49%
EPS This Year
-1.91
from -3.48
EPS Next Year
-1.38
from -1.91
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 118.9M | 134.3M | 157.5M | |||
| Avg | 115.6M | 127.7M | 138.5M | |||
| Low | 109.7M | 117.8M | 113.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -8.8% | 16.2% | 23.3% | |||
| Avg | -11.3% | 10.5% | 8.5% | |||
| Low | -15.9% | 1.9% | -11.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.89 | -1.31 | -1.02 | |||
| Avg | -1.91 | -1.38 | -1.16 | |||
| Low | -1.83 | -1.42 | -1.32 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.